



To: **The Romanian Financial Supervisory Authority**
Financial Instruments and Investments Sector
The Bucharest Stock Exchange
Regulated Spot Market, Category Standard (Shares)

From: **ZENTIVA SA**

CURRENT REPORT

pursuant to art. 139 para. (1) of the Law no. 24/2017 on issuers of financial instruments and market operations and art. 234 para. (1) letter l) of the Financial Supervisory Authority Regulation no. 5/2018 on issuers of financial instruments and market operations

Report date: 26 April 2024

Name of the issuing entity: ZENTIVA SA (the "Company")

Registered office: 50 Theodor Pallady Blvd.
3rd District, Bucharest
Romania

Phone/Fax number: +4021.304.72.00/ +4021.345.40.04

Webpage: www.zentiva.ro

Registration number with the Bucharest Trade Register and sole registration code: J40/363/1991
336206

Share Capital: RON 69,701,704

Number of shares: 697,017,040 shares

Regulated market on which the issued securities are traded: Bucharest Stock Exchange, Main Segment, Category Standard (Shares)

Important events to be reported:

The Company would like to inform its shareholders and investors that on 25 April 2024 it was notified of a statement of claim by the Bucharest Tribunal, 3rd Civil Section, together with *Zentiva k.s.*, a company which is part of the same group as the Company, incorporated and existing under the laws of the Czech Republic, with its seat in Prague 10, Dolni Mecholupy, 130 U Kabelovny St., postal code 102 37, Czech Republic, registered under no. 492 40 030 in the Trade Register maintained by the Municipal Court in Prague, as defendants (the "**Defendants**"), in a lawsuit against *Bayer HealthCare LLC*, with its seat in 100 Bayer Boulevard, Whippany, New Jersey 07981, USA, *Bayer AG*, with its seat in Kaiser-Wilhelm-Allee 1, 51373 Leverkusen, Germany and *Bayer SRL*, with its seat in Sos. Bucharest-Ploiesti, no. 1A, building B, floor 1, Bucharest, District 1, Romania, as claimants (the "**Claimants**").



The case is the subject of file no. 5615/3/2024, has as its object the obligation of the Defendants, jointly and severally, to pay the provisionally established amount of 100,000 Euros and is pending before the court in the first phase of the proceedings.

In the above-mentioned file, the Claimants allege that the Defendants infringed on the rights resulting from the European invention patent EP 2305255, which, according to the Claimants' statements, would have given them an exclusive right to use the chemical substance sorafenib tosylate until the date of December 3, 2022.

Thus, the Claimants request the court to determine the Defendants (i) to pay, jointly and severally, to the Claimants the provisionally established amount of 100,000 Euros, as compensation for acts of infringement of the European invention patent EP 2305255, committed in Romania, and (ii) to pay, jointly and severally, the relevant trial expenses.

Also, the Claimants request the court to order the suspension of the trial of this litigation until the final resolution of file no. 16122/3/2021, pending before the Bucharest Tribunal, 3rd Civil Section. The object of file no. 16122/3/2021 is represented by the annulment of the European invention patent EP 2305255, being introduced by Zentiva k.s. against Bayer HealthCare LLC and the State Invention and Trademark Office.

In connection with the matters set out above, the Company would like to express its commitment to pursue all legal measures with a view to protecting and safeguarding its rights and interests, in the best and long-term interest of all the Company's shareholders and investors. In addition, the Company will bring to the attention of its shareholders and investors updated information in connection with the litigation described above, in accordance with the applicable legal provisions.

Simona Cocos

General Manager